Sameer Parikh
Sameer A. Parikh, is a consultant in the Division of Hematology, Department of Internal Medicine at Mayo Clinic in Rochester, Minnesota. He joined the staff of Mayo Clinic in 2014 and holds the academic rank of associate professor of medicine and assistant professor of oncology, Mayo Clinic College of Medicine and Science. He currently serves as the Chair of the CLL Disease Team at the Mayo Clinic Comprehensive Cancer Center.
Dr. Parikh earned his Bachelor of Medicine and Surgery at the University of Mumbai – Seth G. S. Medical College in Mumbai, India. He completed his residency at St. Francis Hospital, University of Illinois at Chicago and a fellowship in leukemia at University of Texas, M.D. Anderson Cancer Center in Houston. He subsequently completed a hematology/oncology fellowship at Mayo Clinic School of Graduate Medical Education in Rochester, MN.
Dr. Parikh’s research focuses on lymphoproliferative disorders, particularly chronic lymphocytic leukemia (CLL). He is a Principal Investigator of several investigator-initiated and industry-sponsored clinical trials. He is also the Principal Investigator of the Mayo Clinic CLL Database, which includes all patients with a diagnosis of CLL seen in the Division of Hematology at Mayo Clinic in Rochester, MN since 1995, and which is linked to the Mayo Clinic CLL Tissue Bank. He is also a co-investigator on many studies that are funded by the National Institutes of Health and the National Institute on Aging. He serves as the Mayo Clinic representative on the National Comprehensive Cancer Network (NCCN) CLL/SLL/hairy cell leukemia panel.
Financial relationships
-
Attribution:SelfNature of financial relationship:Grant Or ContractIneligible company:JanssenDate added:01/19/2024Date updated:01/19/2024
-
Attribution:SelfNature of financial relationship:Grant Or ContractIneligible company:AstraZenecaDate added:01/19/2024Date updated:01/19/2024
-
Attribution:SelfNature of financial relationship:Grant Or ContractIneligible company:MerckDate added:01/19/2024Date updated:01/19/2024
-
Attribution:SelfNature of financial relationship:Grant Or ContractIneligible company:GenentechDate added:01/19/2024Date updated:01/19/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:PharmacyclicsDate added:01/19/2024Date updated:01/19/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:MerckDate added:01/19/2024Date updated:01/19/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:AstraZenecaDate added:01/19/2024Date updated:01/19/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:JanssenDate added:01/19/2024Date updated:01/19/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:BeiGeneDate added:01/19/2024Date updated:01/19/2024
-
Attribution:SelfNature of financial relationship:Professional ServicesIneligible company:GenentechDate added:01/19/2024Date updated:01/19/2024